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Dear Editor, 
Re: Pro-kinetics prescribing in paediatrics: Evidence on cisapride, domperidone and 
metoclopramide from the UK primary care 
Off-label prescribing of drugs in children is a common practice in an attempt to treat very sick 
children. This practice may expose these children to unnecessary risks – in exchange of uncertain 
benefits. 
We enclosed a manuscript for your review on the prescribing trends of three pro-kinetics: 
domperidone, cisapride and metoclopramide, based on analysis of routinely-collected data from 
primary care in the UK. Our analyses demonstrated remarkable increase in domperidone 
prescriptions in the absence of efficacy and safety evidence, despite withdrawal of a drug of 
similar class, cisapride, in July 2000. The observed trends suggest that published guidelines and 
consensus statements on the treatment of gastro-oesophageal reflux disease in children, when 
produced even without robust efficacy and safety evidence, can influence prescribing practice. 
Recent warnings by the Medicines and Healthcare Products Regulatory Agency in the UK of small 
risks of serious ventricular arrhythmia and sudden cardiac death associated with domperidone 
(May 2012) and restricted indications (May 2014) escalate the importance of being earnest about 
the issue. In October 2014 significant changes in the BNFC also include revisions to domperidone 
as an off-label treatment for GORD in children, with multiple caveats on safety. 
All authors have made substantial contribution in the preparation/approval of the manuscript as 
submitted. The authors confirm that the manuscript has not been published, is being submitted 
only to JPGN and will not be submitted elsewhere while under consideration, and should it be 
published in JPGN, it will not be published elsewhere. The authors take full responsibility of the 
content of the submitted manuscript and any impact it may have on public understanding. The 
study was funded in full by the MHRA Pharmacoepidemiology Research Programme, grant 
number SDS011. The writing and preparation of this paper received no additional funding. 
We look forward to hearing good news from you, and we thank you in advance for your 
consideration. 
 
Yours sincerely, 
Shahrul Mt-Isa (Disclosure: none) and Nicholas M Croft (Disclosure: participated as an 
investigator in a trial of a treatment of reflux in infants funded by Johnson and Johnson) 
 
On behalf of: 
Stephen Tomlin (Disclosure: none) 
Alastair Sutcliffe (Disclosure: none) 
Martin Underwood (Disclosure: none) 
Paula Williamson (Disclosure: none) 
Deborah Ashby (Disclosure: none) 
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ABSTRACT 
Objectives 
Domperidone and metoclopramide are pro-kinetics commonly prescribed off-label to infants 
and younger children in an attempt to treat gastro-oesophageal reflux symptoms. Another 
pro-kinetic drug, cisapride, was used but withdrawn in 2000 in the UK due to serious 
arrhythmic adverse events. MHRA issued safety warnings for domperidone in May 2012, and 
restricted its indications. We report here national primary care prescribing trends and safety 
signals of these drugs in children. 
 
Methods 
We used data from the General Practices Research Database between 1990 and 2006  for 
children <18 years. Descriptive statistics and Poisson regressions were performed to 
characterise prescribing trends. We examined safety signals in nested case–controls studies. 
 
Results 
The proportion of children <2 years old being precribed one of the medications doubled 
during the study period. Prescriptions of domperidone increased 10-fold, mainly following 
the withdrawal of cisapride in 2000. Prescriptions of metoclopramide did not significantly 
change. Despite the increase in prescriptions of domperidone no new safety signals were 
identified. 
 
Conclusions 
These data showed dramatic changes in prescribing of cisapride and domperidone despite the 
lack of good quality supporting evidence. It is possible these prescribing trends were 
influenced by published guidelines. Even if produced without robust efficacy and safety 
evidence, published guidelines can influence clinicians and consequently impact prescribing. 
Therefore, improving the evidence base on pro-kinetics to inform future guidelines is vital. 
The lack of new safety signals over this period would support the development of suitable 
powered clinical studies. 
 
Keywords: clinical practice guideline, gastro oesophageal reflux, paediatrics, cisapride, 
domperidone 
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INTRODUCTION 
It is a common practice to prescribe off-label drugs to children.(1) This is neither 
promoted nor prohibited by the Medicines Act (1968) as informed use of off-label drugs is 
often necessary to treat sick children.(2) In many cases, there is little evidence for efficacy or 
safety of the drugs when used in this population. Over 50% of medicines used in children in 
the European Union have never been studied in this population.(3) 
 
An example of this is the use of pro-kinetic drugs in children with gastro-oesophageal 
reflux disease (GORD). GORD is an involuntary passage of gastric contents into the 
oesophagus and is a common problem in infants.(4) GORD is generally benign and resolves 
between 12-24 months old, but in some cases a drug treatment is used in an attempt to control 
worsening or persistence of the symptoms. Pro-kinetics such as cisapride, domperidone and 
metoclopramide have been used to treat GORD symptoms in children, but their licensing 
indications in children are restricted to nausea and vomiting. Cisapride was withdrawn in July 
2000 following cardiac adverse reactions in adults. A drug of similar class, domperidone, 
emerged as an alternative following the withdrawal. However, in May 2012 the UK 
Medicines and Healthcare Products Regulatory Agency (MHRA) warned of the small risk of 
serious ventricular arrhythmia and sudden cardiac death associated with domperidone, with 
elevated risk in those consuming daily doses of more than 30mg.(5) The MHRA 
subsequently revised the contraindications of domperidone and enforced restricted use in 
May 2014 for adults, while acknowledging further research is needed in children;(6) and later 
placed it under additional monitoring (Black Triangle) in July 2014.(7) These changes 
triggered a revision to the off-label use of domperidone for GORD in the UK British National 
Formulary for Children (BNFC) in October 2014.(8) Other treatment options are available, 
all with limited evidence of efficacy.(4;9-13) 
 
A Cochrane systematic review on cisapride after its withdrawal concluded that there 
was no clear evidence that cisapride reduces GORD symptoms and suggested substantial 
publication bias towards studies showing positive effect of cisapride.(14) A systematic 
review of domperidone concluded that there is a minimal evidence for efficacy of 
domperidone in reducing GORD symptoms but very few trials were available.(15) 
Systematic reviews of metoclopramide concluded that there may be some benefit against 
placebo,(12) but there is insufficient evidence to support or oppose its use for GORD in 
infants  since very few trials were available and mostly were of short duration.(16) 
 
GORMET (Gastro-Oesophageal Reflux Medicines – Evidence for Trials) was a study 
designed to explore the potential of the General Practice Research Database (GPRD) for 
informing clinical trial design on safety of  medicines used off-label in primary care for the 
treatment of GORD symptoms in children.(17) The study population was extracted from 
approximately 3.6 million active patients from around 433 practices participating in GPRD, 
covering 5.5% of the UK population (http://www.gprd.com in April 2008; 
http://www.cprd.com from 29/03/2012).(18)  
 
We address chronological changes in prescribing trends of cisapride, domperidone 
and metoclopramide in children, as explored in GORMET.(17) We consider external factors 
that may have influenced the trends observed, particularly the emergence of paediatric 
guidelines on the management of GORD during this critical period. The side-effects of these 
drugs are well-documented for adult use but not in children. Therefore, we also looked for 
signs of any increased clinical events associated with these drugs that may be causally-related 
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(safety signals) with their use in children to identify potential safety issues, particularly for 
younger children where the indications were likely to be for GORD. 
 
MATERIALS AND METHODS 
We used GORMET data from the GPRD for children aged under 18 years old 
between 1990 and 2006 who were prescribed cisapride (N=1,497), domperidone (N=9,319), 
or metoclopramide (N=17,985), and had at least three months of follow-up data recorded.(17) 
Each child was matched by age and sex to four children without any prescription of the three 
drugs. The number of all children in GPRD under 18 years old, by year, during the same time 
period were used as denominators.  
 
We used Poisson regression adjusted for the size of the underlying child population in 
the GPRD by year to calculate incidence rates (number of new children per million starting 
prescription in a particular year). We calculated these rates for all children initially, and then 
for the subset of children under two years old (<2) and for those two years old and older ( 2) 
because the likely different indications in these two age groups. The prescribing would be 
expected to be somewhat different between these groups of children. We discuss the trends of 
prescriptions, and the influence of paediatric guidelines on GORD.  
 
We hypothesised that side-effects listed in the British National Formulary(19;20) for 
all three drugs were known safety signals for children. We calculated the proportional 
reporting ratios of other drug-event pairs to generate hypotheses of unknown safety 
signals.(21;22) We conducted nested case-control studies for the unknown safety signals, and 
argued the drug-event causality according to Bradford-Hill.(23) 
 
Ethical approval for this study was obtained from the Independent Scientific Advisory 
Committee for MHRA database research (project number SDS011). 
 
RESULTS 
Data 
Table 1 shows the number of children whose data were used in the analyses. Because 
GPRD does not record clear diagnosis of GORD, the data extracted contain children 
prescribed with cisapride, domperidone, and metoclopramide for any indication. The 
prescription of these drugs is most likely for the treatment of recurrent vomiting due to 
GORD in children <2. In children  2, GORD indication is less common; and these drugs 
may be prescribed for the licensed indications of nausea and vomiting from various causes 
including chemotherapy and migraine. 
 
Incidence rates of prescribing 
There was a small increase in the percentage of all children being prescribed one of 
these three medications from 0.09% (1990) to 0.11% (2006). Use in <2’s increased markedly 
from 0.4% to 0.75% whereas use in those  2 decreased from 0.5% to 0.35%. 
 
The annual incidence rates of cisapride (1990-2000) and domperidone (1990-2006) 
prescription in all children increased by 24.6% (95% CI 10.7%-38.6%) and 7.5% (95% CI 
6.8%-8.1%), respectively. That of metoclopramide (1990-2006) in all children declined by 
4.3% (95% CI 3.4%-5.3%).  
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Figure 1 shows the incidence rates per million children by age group and year. There 
was a dramatic increase in incidence rates in children < 2 years old being prescribed 
domperidone following the withdrawal of cisapride in July 2000. A much smaller increase 
was observed in those  2 years old. The incidence rates in those prescribed with 
metoclopramide were similar across age groups, with some evidence of a decline.  
 
Age at start of therapy 
The median starting ages in children <2 years old were 6 (inter-quartile range, IQR 4-
10), 5 (IQR 3-10), 14 (IQR 9-19) months old for cisapride, domperidone and 
metoclopramide, respectively. The starting age decreased over time in children <2 years old 
among those on cisapride and domperidone, whilst those on metoclopramide did not 
significantly vary.  
 
The median starting ages in children  2 years old were 10 (IQR 5-15), 15 (IQR 11-
17), and 14 (IQR 9-16) years old for cisapride, domperidone and metoclopramide, 
respectively. There were no marked variations in starting age over time for all three drugs in 
this group.  
 
Therapy amount and duration 
The mean number of prescriptions issued per child <2 years old were generally 
greater than those issued to children  2 years old (Figure 2). Not only there were more 
prescriptions, the mean therapy duration were generally longer in the younger group of 
children than the older one (Figure 3). Both trends fit with the indications for chronic GORD 
symptoms in younger children and the short-term prescribing for licensed indications such as 
nausea, migraines and following a chemotherapy in older children. Additionally, increasing 
trends of therapy amount and duration were most pronounced in the domperidone cohorts. 
 
Emergence of guidelines and prescribing trends 
Several guidelines supporting the prescribing of cisapride,(24-27) domperidone (24-
26) and metoclopramide (24-26) to children <2 years old emerged over the years and may be 
accountable for some of these dramatic changes. The greatest increased number of cisapride 
prescriptions was observed between 1994 and 1998. A steady increase of domperidone 
prescriptions in <2 years was also observed particularly after the year 2000. The prescribing 
of metoclopramide decreased over the same time period. Figure 4 demonstrates a possible 
temporal effect in response to these best known guidelines. 
 
Safety signals 
The results from these analyses were presented in full in GORMET report.(17) 
Following the systematic approach, we did not uncover any new causally-related safety 
issues in children prescribed with these drugs. Only diarrhoea was associated with 
domperidone prescription in children <2 years old with incidence rates ratio of 1.26 (95% CI 
1.08-1.47). However, the unknown safety signals were, in general, associated with 
concomitant medications and illnesses, and increased dose or duration of pro-kinetics use. 
 
DISCUSSION 
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These data show marked changes in the prescription of cisapride, and then 
domperidone in children <2 years old despite the lack of marketing authorisation for use in 
this population or good quality published evidence of efficacy and safety to support these 
changes. The drivers for these changes are likely to have been a combination of marketing 
from the companies, publication of papers and publication of guidelines by professional 
societies. A New Zealand study showed similar trends of prescribing for cisapride; and 
suggests delayed response to safety alerts by the general practitioners (GPs) – ‘this delay was 
more pronounced with paediatricians when the prescribing practice is already embedded in 
their routine care’.(28) There is also a suggestion that clinicians adhere to guidelines 
poorly,(29) but there is no research attempting to link prescription rates to clinical guidelines 
in the literature. 
 
The main limitations of this study are biases and underestimation. The GPRD only 
records drug prescription, but it is unknown whether the drugs were actually consumed by the 
patients as prescribed. Many prescriptions of these drugs may have been initated in the 
hospitals by paediatricians, neonatologists or specialist paediatric gastroenterologists, 
therefore some early prescriptions would not have been captured in the GPRD. Consequently, 
the prescribing rates are likely to be an underestimate of the true prescribing. Another 
limitation of this article is that it presents somewhat older prescribing data (1990 – 2006). We 
believe, however, these periods cover the critical time points of the changing guidelines and 
evidence of pro-kinetics in children. Moreover, any recent data would not change the 
temporal trends of the prescribing of cisapride, domperidone and metoclopramide that we 
observed in the general practices. This historical evidence may be used to guide future 
learning and continuing debates in this area. 
 
Cisapride was licensed in the UK in 1988 for the treatment of GORD in patients over 
12 years old. Cisapride suspension, which would be the form of choice in the prescribing for 
younger children, became available in the UK in mid-1992 when we also observed an initial 
increase in the rates of cisapride prescribing in children. In 1993, a working group of the the 
European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 
recommended cisapride as the first drug treatment in children and infants with GORD 
following ‘failed lifestyle changes over 1-2 weeks’.(25;30) Despite acknowledging limited 
data were available, domperidone and metoclopramide were listed as alternatives in the face 
of no response to cisapride. 
 
The ESPGHAN guidelines and the introduction of cisapride suspension in 1992 in the 
UK were followed by the observed steep increase in the prescribing of cisapride between 
1994 and 1998 when the medication became widely available. However, reports of prolonged 
QT intervals and fatal cardiac arrhythmias events among adults on cisapride treatment soon 
emerged around 1997. 
 
The profusion of publications and practice guidelines suggesting a benefit from 
cisapride may have influenced clinicians’ decisions to prescribe cisapride.(31) The guidelines 
on treating reflux with cisapride were based on small, mostly unblinded, clinical trials which 
were evaluated qualitatively by a working group within the ESPGHAN.(25) The process of 
drawing up the guidelines, and conflicts of interest were not clearly defined in the published 
document. There was no evidence of systematic critical evaluation as would be expected now 
in the UK in the development of  NICE or SIGN guidelines.(32;33) Another factor that may 
bias decisions and which was not openly addressed in many publications of that period was 
the disclosure of industry support for individuals in the working group who could influence 
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the final document. Therefore, in retrospect, for paediatricians and GPs to react positively to 
these guidelines was not fully warranted; instead the guidelines should have been challenged 
for the lack of evidence. 
 
As part of post-marketing safety monitoring, Janssen Pharmaceutica, who 
manufactured cisapride and domperidone, issued safety warnings on cisapride in June 1998. 
This was followed by a reduction in cisapride prescribing rate, suggesting that GPs became 
more cautious when prescribing cisapride to children. Nevertheless, ESPGHAN and 
NASPGHAN (North American Society of Paediatric Gastroenterology Hepatology and 
Nutrition) remained openly and largely supportive of the efficacy and safety of 
cisapride.(26;27) However, the updated 2009 guideline on GORD in infants developed 
between ESPGHAN and NASPGHAN warns that ‘potential adverse effects of currently 
available pro-kinetic agents outweight the potential benefits of these medications for the 
treatment of GORD’.(34) It emphasises there is insufficient evidence of clinical efficacy to 
justify routine use of bethanecol, metoclopramide, cisapride or domperidone.(34) Unlike the 
initial ESPGHAN guideline, this report was developed systematically with full disclosure of 
conflicts of interest.  
 
Accumulating safety evidence from the UK Yellow Card Scheme and other 
worldwide reports finally prompted the MHRA and the Committee on Safety of Medicines to 
take action. Marketing authorisation of cisapride in the UK was suspended on 28 July 2000, 
and subsequently withdrawn. 
 
Since the withdrawal of cisapride, with less evidence of efficacy and safety, 
domperidone has become widely prescribed to children for the treatment of GORD symptoms 
despite the fact that the BNFC does not and never did recommend the use of domperidone in 
children with GORD symptoms. Over fourteen years later, the Paediatric Formulary 
Committee continues to recognise that domperidone may be used when other interventions 
have been tried; despite unconvincing evidence of efficacy.(8) The data suggest that 
domperidone prescribing in children rapidly increased in primary care. Prescribing in North 
America did not go down this route; possibly because the NASPGHAN guidelines never had 
mentioned domperidone as an alternative.(27) 
 
It is possible that the influx in domperidone prescription was initiated at first as a 
replacement for cisapride where there had been a large increase previously. This would fit 
with the ESPGHAN guidelines in 1993 and the report published in 1997, which advised 
domperidone and metoclopramide might be considered as alternatives to cisapride if there 
was no response to it.(24;25) However, the perceived safety of domperidone with presumed 
efficacy for the treatment of GORD symptoms in children was most likely the reason for the 
subsequent rise over the following years. A study in Belgium also observed increasing trend 
of acid suppressants use in children that could as well be partly contributed by the withdrawal 
of cisapride.(35)  
 
 Metoclopramide has lost popularity, possibly because of the known extrapyramidal 
adverse reactions, alongside several early studies showing the superiority of domperidone to 
metoclopramide.(36-39) It is primarily used in older children with nausea and sickness rather 
than infants with reflux. Metoclopramide prescriptions may continue to decline in response to 
a ‘black box’ warning for tardive dyskinesia adverse reactions issued by the FDA on 29 
February 2009.(40) However, the concerns on long-term adverse reactions in children who 
were affected by the drugs still remain and need further investigation. 
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The decline in age over time when children were started on cisapride and 
domperidone therapy indicates that paediatricians and/or GPs did react positively to these 
guidelines. The increasing number of prescriptions per child and longer therapy duration over 
time suggest GPs were getting more comfortable prescribing these drugs to children; 
although this may be a sign that these drugs were not very effective and there were 
continuing symptoms, or that may be the children were suffering a chronic disease and did 
receive some clinical benefit. For infants with reflux, the reality is no-one knows if these 
drugs are of any use and importance. It is quite possible that they may have a role, but the 
evidence is currently simply not there.(14;15)  
 
The guidelines may not be all that have contributed to these changes – societal factors 
such as anxious and more inexperienced parents could be less accepting of having infants 
with, what is for the majority a benign and self-limiting disorder, and chose to turn to drugs 
treatment for help. The increase in the proportion of infants being treated over the course of 
the study would be consistent with this. These are only speculations and cannot be explored 
using these data. Despite these changes in off-label prescribing of pro-kinetics in children, 
extensive analyses in GORMET did not reveal any safety signal that may be causally related 
to the use of cisapride, domperidone or metoclopramide.(17) Our results on safety are also 
consistent with MHRA’s recommendation of reduced dose and duration of domperidone use 
in adults.(6) Our analyses support the development of new well-designed clinical studies to 
further investigate the efficacy and safety of domperidone use in children <2 for the treatment 
of GORD.  
 
Off-label drugs prescribing may lead to many unknown complications when the 
efficacy and safety have never been formally assessed in the intended population. Vulnerable 
populations like children are affected by this trade, and require more regulated and 
transparent intervention. More importantly, the efficacy and safety of the drugs that are 
widely used off-label, such as domperidone in children, need to be formally assessed in the 
representative population in a controlled environment to make its use safer. 
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Figure 1 Mean incidence rates per million children by year and age group 
 
 
Figure 2 Mean number of prescriptions per child by year and age group 
Data for cisapride after year 2000 was truncated. 
 
 
Figure 3 Mean therapy duration per prescription by year and age group  
Data for cisapride after year 2000 was truncated. 
 
 
Figure 4 Number of prescriptions of cisapride, domperidone and metoclopramide prescribed 
per 10,000 children below two years old by year and temporal events 
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Table 1 Summary data, number of children whose prescription data were analysed in that 
year (% of whom were under 2 years old) unless otherwise specified 
 
Denominator
a 
Cisapride Domperidone Metoclopramide 
1990-2006
b 
n/a 1497 (n/a) 9319 (n/a) 17985 (n/a) 
1990 461712 (18%) 7 (14%) 171 (4%) 1030 (7%) 
1991 497281 (18%) 30 (3%) 259 (6%) 1620 (10%) 
1992 532257 (18%) 101 (8%) 302 (2%) 1642 (12%) 
1993 566534 (17%) 225 (30%) 336 (2%) 1660 (8%) 
1994 604001 (17%) 353 (29%) 359 (2%) 1789 (7%) 
1995 640503 (16%) 734 (45%) 457 (3%) 1732 (7%) 
1996 672740 (15%) 1208 (51%) 476 (5%) 1748 (6%) 
1997 695884 (15%) 1406 (46%) 590 (10%) 1692 (7%) 
1998 708868 (15%) 1540 (48%) 692 (9%) 1711 (7%) 
1999 720343 (15%) 1290 (38%) 962 (14%) 1683 (7%) 
2000 728945 (14%) 678 (31%) 1364 (23%) 1802 (5%) 
2001 732916 (14%) 9 (0%) 1786 (23%) 1705 (7%) 
2002 738181 (13%) 24 (0%) 2068 (26%) 1643 (6%) 
2003 750996 (13%) 28 (4%) 2480 (32%) 1559 (8%) 
2004 762111 (13%) 5 (0%) 3049 (36%) 1316 (7%) 
2005 774650 (14%) 0 (0%) 3614 (37%) 1207 (6%) 
2006 781167 (14%) 0 (0%) 4329 (40%) 1232 (6%) 
a
 Only the count data of number of children were extracted and used in analyses. 
b
 Total number of unique child, among whom may have multiple prescriptions and/or 
prescriptions spanning over one year. 
n/a = not applicable 
Table 1
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